Substance and claimed effects

Resistance training (RT) — also called strength training or weight training — is any modality where skeletal muscle contracts against an external load heavy enough to require near-maximal effort within a finite repetition window, typically 5–30 reps per set. Free weights, machines, bands, bodyweight progressions, and kettlebells all qualify; the load and the proximity to failure are what classify the work, not the implement. The literature consistently treats the dose along three axes: weekly volume (hard sets per muscle group), frequency (sessions touching a given muscle per week), and intensity / proximity to failure (effort, often expressed as reps in reserve or % 1RM). The claimed consequences fall into six clusters this entry covers holistically: (1) increases in muscle mass and strength Schoenfeld 2017 Ralston 2017; (2) increases in bone mineral density at clinically relevant sites Watson 2018 Howe 2011; (3) prevention and partial reversal of sarcopenia and the frailty / falls cascade in older adults Liu & Latham 2009 Fragala 2019; (4) improvements in glucose handling and insulin sensitivity, with HbA_1c reduction in type 2 diabetes and lower incident T2D risk in healthy adults Sigal 2007 Grøntved 2012 Ishiguro 2016; (5) reductions in all-cause, cardiovascular, and cancer mortality independent of aerobic exercise Saeidifard 2019 Momma 2022 Stamatakis 2018; (6) improvements in mood, with meaningful reductions in depressive symptoms in clinical and subclinical populations Gordon 2018. The dossier treats each of these as in scope.

Evidence by addressing question

Mechanism

RT loads contractile tissue beyond habitual stress, activating mechanotransduction pathways (most prominently mTORC1 via integrin and phospholipase D / phosphatidic acid signalling) that elevate muscle protein synthesis for 24–48 hours after a session McLeod 2019. Net protein balance becomes positive when adequate dietary protein is available; over weeks the muscle fibre cross-sectional area increases (hypertrophy), and over months whole-muscle mass rises. Strength gains run on a partially separate track — early gains (weeks 1–6) are dominated by neural adaptation (motor unit recruitment, rate coding, intramuscular coordination), with hypertrophy contributing more thereafter ACSM 2009.

Mechanical loading also drives bone adaptation via the osteocyte-mediated response to strain. Site-specific high-magnitude, low-repetition loading is the most osteogenic stimulus — heavy axial compression at the spine and hip outperforms walking and low-load circuit training by a wide margin Watson 2018 Howe 2011. Trabecular bone in the femoral neck and lumbar vertebrae remodels in response to repeated peak strains in the 1.5–2× bodyweight range delivered through compound lifts.

For glucose handling, the mechanism is muscle as the principal sink for postprandial glucose. Resistance training enlarges this sink in two ways: increased muscle mass (more GLUT4 transporters available) and increased non-insulin-dependent glucose uptake during and after exercise via contraction-stimulated GLUT4 translocation. RT also reduces visceral adipose tissue and intramyocellular lipid, both of which contribute to insulin resistance Strasser & Pesta 2013. The mortality effect is thought to be a composite: preserved muscle mass and strength, improved cardiometabolic risk factors, reduced falls / fractures, and possibly direct effects of myokines (IL-6, irisin, BDNF) released during contraction McLeod 2019 Volaklis 2015.

Evidence — muscle and strength

The volume meta-analysis by Schoenfeld 2017 pooled 15 RCTs and found a dose-response: weekly sets per muscle group predicted hypertrophy, with the upper threshold of demonstrated benefit around 10+ sets/week for trained populations. Ralston 2017 meta-analysed 9 RCTs on strength and found a similar dose-response — high volume (5+ sets/exercise/session) outperformed low volume by an effect size of ~0.5 on 1RM. Frequency, when total volume is equated, is at most a small effect: Schoenfeld 2016 found 2 sessions/week per muscle slightly outperformed 1 session/week for hypertrophy, with no clear advantage to 3+. Strength gains in untrained adults run 25–50% in 8–12 weeks across modalities; hypertrophy is on the order of 1–2 kg of lean mass in the first 12 weeks in beginners, slowing to ~0.5 kg/month thereafter and approaching asymptote in trained lifters after 3–5 years ACSM 2009.

Evidence — bone

The LIFTMOR trial Watson 2018 randomised 101 postmenopausal women with low bone mass to 8 months of high-intensity resistance and impact training (HIRIT — deadlift, overhead press, back squat at 80–85% 1RM, plus jumping chin-ups) versus a low-intensity home programme. The HIRIT group gained lumbar spine BMD (~+2.9%) and femoral neck BMD (~+0.3%) versus losses in the control group; functional measures (timed-up-and-go, vertical jump, back extensor strength) all favoured HIRIT. The follow-up LIFTMOR-M trial in middle-aged and older men with osteopenia replicated the spine effect Harding 2020. The Cochrane review Howe 2011 across 43 trials concluded that progressive resistance strength training of the lower limbs is the most effective single exercise modality for hip BMD in postmenopausal women. Effect sizes are modest in percentage terms (~1–3% BMD over 6–12 months) but clinically meaningful — every 1 standard deviation of femoral neck BMD predicts ~2.6× hip fracture risk.

Evidence — sarcopenia and physical function in older adults

The foundational demonstration was Frontera 1988: 12 weeks of high-intensity knee extensor and flexor training in men aged 60–72 produced 107% and 226% strength gains and 9–11% increases in muscle cross-sectional area — undermining the prior assumption that aged muscle was refractory to hypertrophy. The Cochrane review by Liu & Latham 2009 pooled 121 trials with 6,700 older participants and found progressive resistance training improved gait speed (mean difference +0.08 m/s), chair-stand time, stair-climb power, and self-reported function. The NSCA position statement Fragala 2019 codifies recommendations for adults over 50: 2–3 sessions/week, multi-joint exercises, moderate to high intensity (70–85% 1RM), explicit power training (fast concentric tempo). Age does not abolish the adaptation — even nonagenarians gain strength on PRT — but the relative rate of gain is preserved while absolute peak achievable strength is lower.

Evidence — glucose handling

The DARE trial Sigal 2007 randomised 251 adults with type 2 diabetes to aerobic only, resistance only, combined, or waitlist for 22 weeks. Resistance training alone reduced HbA_1c by 0.38 percentage points; combined training reduced it by 0.97 points — a clinically meaningful effect comparable to adding a second oral hypoglycaemic. The Ishiguro meta-analysis Ishiguro 2016 across 27 RCTs in T2D found RT reduced HbA_1c by 0.39% on average; benefit was concentrated in supervised programmes and in those using moderate-to-high intensity. In healthy men, the Health Professionals Follow-Up Study Grøntved 2012 followed 32,002 men for up to 18 years and found those who reported ≥150 minutes/week of weight training had a 34% lower risk of incident T2D, independent of aerobic activity; the effect was dose-responsive across all volumes from 1 minute to 150+ minutes/week.

Evidence — mortality and chronic disease

Several large meta-analyses converge on a 10–20% reduction in all-cause mortality from regular muscle-strengthening activity, with the dose-response curve flattening at ~30–60 minutes/week and providing no additional benefit (and possibly a small adverse trend) past ~140 minutes/week. Momma 2022 pooled 16 prospective cohort studies and found muscle-strengthening at ~30–60 min/week was associated with 10–17% lower all-cause, cardiovascular, total cancer, diabetes, and lung cancer mortality. Saeidifard 2019 pooled 11 cohorts (370,256 participants) and reported a 21% lower all-cause mortality risk and 17% lower CVD mortality for those doing any RT vs none, with effects independent of aerobic exercise. Stamatakis 2018 in 11 UK cohorts (~80,000 adults) found strength-promoting exercise associated with 23% lower all-cause and 31% lower cancer mortality, again independently of aerobic exercise. García-Hermoso 2018 pooled 38 cohorts (~2 million participants) and found higher muscular strength (top vs bottom third of grip / leg strength) predicted 31% lower all-cause mortality — a relationship of similar magnitude to that observed for V_O2max. Volaklis 2015 reviewed the strength-mortality literature with similar conclusions across populations.

Evidence — mood

The Gordon 2018 meta-analysis pooled 33 RCTs (1,877 participants) and found resistance training reduced depressive symptoms with a moderate-to-large effect (Hedges' g = 0.66, 95% CI 0.48–0.83), with the effect independent of training volume, intensity, and baseline depression. Effects were larger in adults with depressive symptoms at baseline but present in subclinical samples too. Mechanism candidates include myokine signalling (BDNF, IGF-1), mastery / self-efficacy, social engagement in group settings, and improved sleep.

Protocol

Synthesis from the volume, frequency, and progression literature plus the NSCA older-adults position stand Fragala 2019 ACSM 2009 Schoenfeld 2017 Schoenfeld 2016:

• Frequency: 2–3 full-body or upper/lower split sessions/week; each muscle group hit twice/week.
• Volume: ~10 hard sets per muscle group per week as a starting working dose; ramp toward 15–20 sets for trained lifters in muscles that lag.
• Intensity: 5–15 reps to within 1–3 reps of failure on most working sets; periodic heavier work (3–5 reps) for strength and bone signal.
• Selection: compound movements (squat / deadlift / hinge variants, press, row, pull-up) form the backbone; isolation work added for lagging muscles or rehab.
• Progression: add load, reps, or sets weekly while form holds (the operationalisation of "progressive overload").
• Duration: 30–60 minutes/session.
• Time-to-effect: strength gains in 2–4 weeks, visible body composition in 8–12 weeks, BMD response over 6–12 months, mortality risk reduction over years.

The WHO 2020 physical activity guideline WHO 2020 recommends muscle-strengthening of all major muscle groups ≥2 days/week for adults, on top of aerobic activity — not in place of it.

Contraindications and safety

RT is safer than its reputation in most populations including older adults with controlled chronic disease Fragala 2019 Westcott 2012. Real cautions: uncontrolled hypertension (the Valsalva manoeuvre during heavy lifts spikes systolic pressure, transient peaks above 300 mmHg have been measured), recent cardiac event or unstable angina (clinician sign-off required), recent eye surgery or active retinopathy (intraocular pressure spikes), recent hernia or aortic aneurysm. Injury risk in supervised programmes is ~1 injury per 1,000 training hours — lower than running. The dominant injury mode is form breakdown under fatigue or excessive load; technique-first programming with a coach for the first 6–12 weeks is the standard mitigation.

Misconceptions

Several persistent ones documented in Westcott 2012 and Fragala 2019: (1) heavy lifting is dangerous for older adults — the evidence shows the opposite; load tolerance is maintained and the absence of loading is what causes the sarcopenia / falls cascade. (2) Women bulk easily from lifting — testosterone levels make male-pattern hypertrophy biologically very difficult; women on the same programme gain strength at a similar relative rate but mass at roughly 50–70% the absolute rate. (3) Cardio is more important for mortality than strength training — the cohort data show RT contributes an additive, partially independent reduction (Stamatakis, Saeidifard, Momma), so the comparison is false. (4) Machines are inferior to free weights — for hypertrophy outcomes the evidence is essentially equivocal; machines are safer for beginners and for training to failure. (5) You can spot-reduce fat by training a body part — there is no evidence for this; RT changes total and visceral fat in proportion to overall energy expenditure.

Failure modes

The dominant pattern in trainees who plateau or quit: (1) under-loading — never approaching genuine failure, so the stimulus is sub-threshold; (2) no progression — same loads and reps for months; (3) cardio dilution — high-volume aerobic sessions on lifting days blunting hypertrophy via the interference effect; (4) insufficient protein — net protein balance never reliably positive at <1.4 g/kg/day in active adults; (5) chronic sleep debt — recovery and strength gain attenuate measurably below 6 hours/night; (6) over-volume burnout — particularly in trained lifters past 20 sets/week per muscle, returns are marginal and joint / tendon overuse risk rises.

Stakes (absence-projection)

Without RT, the population trajectory is well characterised: muscle mass declines ~1% per year after age 30 and accelerates to ~1.5–2% per year after 60; strength declines faster than mass (~2–3%/year after 60), driven by motor unit loss and neuromuscular junction dysfunction Fragala 2019 McLeod 2019. Functional consequences: by 70, ~30% of community-dwelling adults cannot rise from a chair without using hands; sarcopenia confers ~3× higher risk of falls and ~5× higher fracture risk after a fall. The mortality data García-Hermoso 2018 Volaklis 2015 are stark: the lowest tertile of grip / leg strength carries roughly 1.5× higher all-cause mortality than the top tertile, with strength a stronger predictor than blood pressure or LDL cholesterol in most cohorts.

Payoff (presence-projection)

Time-staged expectations from the trial literature: novice trainees feel improved energy and posture within 2–4 weeks (largely neural); visible muscle change in mirrors at 6–8 weeks; clothes-fit changes at 8–12 weeks ACSM 2009. Glucose handling improves measurably (HbA_1c) at 12–24 weeks in those starting elevated Sigal 2007 Ishiguro 2016. Mood response in depressive samples emerges over 6–12 weeks Gordon 2018. BMD improvements detectable at 6–12 months Watson 2018. Mortality reduction is a years-decades horizon — visible only in cohort statistics, not in the individual's daily experience, but real and partly independent of any other intervention.

Practicalities

A commercial gym membership runs ~$20–80/month in most markets; a home setup (barbell, plates, rack, bench) is a one-time $500–2,000 outlay that pays back vs gym fees in 1–3 years. Two to three sessions/week at 30–60 minutes is the realistic time commitment — roughly 2–3 hours/week of training plus transit. The largest practical friction is the first 6–12 weeks of technique acquisition; the value of one block of coaching here is high. Trainees over 50 benefit from supervised onboarding Fragala 2019.

The credibility range

Optimist case

RT is among the most-studied non-pharmaceutical interventions in modern medicine. The evidence base is broad (hypertrophy, strength, bone, glucose, mortality, mood) and deep (RCTs, meta-analyses, prospective cohorts of millions). Multiple effects are partially independent of aerobic exercise Stamatakis 2018 Saeidifard 2019, meaning RT is not a substitute for cardio but an additive intervention. Effect sizes are large for muscle / strength / function (the primary outcomes) and clinically meaningful for the downstream metabolic and mortality outcomes. The minimum effective dose is small — even 30–60 min/week of muscle-strengthening shows mortality benefit — making this a high-yield, accessible intervention. Cost is low (free bodyweight options exist) and effort, while substantial, is finite and decomposable. The optimist call: this is one of the highest-leverage things any adult can do, especially after 40, and the case strengthens with age.

Skeptic case

The mortality cohort data is observational and subject to healthy-volunteer bias: people who lift weights are more likely to be lean, non-smoking, employed, and socioeconomically advantaged. Adjustment models can partially address this but cannot rule it out. The RT-and-mortality dose-response curves Momma 2022 show plateau and possible inverse-J at higher doses, hinting that confounding may be doing more work than mechanism at the top end. RT's hypertrophy and strength effects are unambiguous; the cardiometabolic effects are smaller and noisier than aerobic exercise's. Adherence in the general population is poor — population estimates put muscle-strengthening adherence at 20–30% of adults, vs ~50% for aerobic — so the "translational" effect may be smaller than RCT effect sizes suggest. The injury rate is low in supervised settings but rises with unsupervised self-coaching.

Author's call

Lands strongly on the optimist side. The muscle / strength / bone / sarcopenia evidence is settled and the effect sizes are large. The glucose handling evidence is convergent across cohorts and trials. The mortality evidence is observational but consistent across many cohorts in many countries, partially independent of aerobic exercise, and biologically plausible via muscle's metabolic and structural roles. The depression evidence is RCT-grade and the effect is clinically meaningful. The skeptic case rightly tempers the upper end of the mortality dose-response and reminds us cohort data has limits, but does not undermine the core claim. The catalogue's article scores `evidence: 5`, `controversy: 1` — there is real, minor field debate on optimal volume / frequency, but no foundational disagreement about whether RT works or whether it should be in adults' weekly routine.

Stakeholder and incentive map

• Pushing RT: NSCA, ACSM, WHO, sports-medicine guidelines bodies (professional / public-health incentive). Personal trainers, coaches, supplement industry (commercial incentive — supplement makers benefit downstream from gym culture). Gyms and equipment manufacturers (direct commercial). The fitness influencer ecosystem (audience / commercial incentive — bias toward more-is-better).
• Pushing back / under-emphasising: primary care historically defaulted to aerobic-only advice for cardiometabolic patients (institutional inertia, simpler protocol); some older-adult medicine has been overly conservative about heavy loading (liability and habit); the cardio-centric fitness culture (running / cycling) has been slow to update on the additive case for RT. Healthcare incentives largely don't reward prevention.
• Net signal: the field is one of those rare cases where professional, commercial, public-health, community, and mechanistic incentives mostly align in the same direction. The risk is hype on volume / intensity from influencer adjacents, not foundational dispute.

Population variability

• Sex: men gain absolute mass faster; relative strength gains are similar; bone response similar magnitude but starting from a lower baseline in women. Postmenopausal women have the highest absolute payoff for BMD given the steepest decline trajectory.
• Age: all ages respond, including 80s and 90s Liu & Latham 2009. Older adults take longer for tendon and connective-tissue adaptation; programming favours longer warm-ups, lower-impact alternatives where joints are degraded, and explicit power work.
• Baseline status: sedentary novices show the largest absolute gains in the first 6 months. Detrained returners regain prior peaks faster than novices reach them (muscle memory via myonuclear retention).
• Genotype: response variance is real — high responders gain 2–3× the mass / strength of low responders on the same programme, partly mediated by satellite cell content and ribosome biogenesis capacity. The non-responder fraction shrinks toward zero when volume and intensity are increased.
• Type 2 diabetes: supervised, moderate-to-high-intensity protocols are reliably effective; home-based, low-intensity protocols show smaller effects.
• Comorbidities: osteoarthritis is generally improved by RT (not worsened) when load is progressed appropriately. Chronic kidney disease does not contraindicate RT but high-protein diets common in trainees need clinical management. Adults on blood-pressure medication require dose monitoring as adaptation reduces resting BP.

Knowledge gaps

Open questions: (1) the upper end of the mortality dose-response — whether the apparent plateau / J-curve past ~140 min/week reflects true biology, confounding, or measurement; (2) optimal protocol for cognition / focus, where the evidence is thinner than for aerobic exercise; (3) whether eccentric-emphasised protocols offer extra benefit per unit time, suggested by mechanism but undertested at population scale; (4) whether minimum-effective-dose protocols (e.g., one set to failure per muscle, 2x/week) produce most of the benefit in time-constrained adults, a question with several promising small RCTs but no large definitive trial; (5) the population-level effect if RT adherence moved from ~25% to ~50% — modelling suggests large, but only one country (Finland) has attempted muscle-strengthening promotion at scale. Evidence that would change the call: a large pragmatic trial showing the mortality association is mediated entirely by aerobic fitness; a definitive ceiling effect at very low volumes; emergent safety signal in older adults under heavy load (not seen in current data).

Scope vs the brief. The brief named muscle mass, strength, bone density, sarcopenia, glucose handling, and all-cause mortality. All six are covered end-to-end. The dossier also surfaced robust evidence on mood (Gordon 2018 meta-analysis) and modest but real evidence on sleep and cognition; the holistic-scoring rule required scoring those non-zero, so the article gives each at least a paragraph in the evidence section. No scope narrowing relative to the brief.

Rating calls worth noting.

• Longevity 5 vs 4. Went with 5. The effect replicates across multiple meta-analyses (Saeidifard, Momma, Stamatakis, García-Hermoso), covers all-cause + CVD + cancer + T2D endpoints, holds independent of aerobic exercise, and runs over data on millions of participants. Meets the "dominant longevity effect" anchor.
• Effort burden 3 vs 4. Settled on 3. Two-to-three sessions a week of focused effort is substantial and the discomfort is genuine, but the practice doesn't dominate the day or require restructuring most of waking life the way the level-4 anchor implies.
• Focus 2. The cognitive evidence for resistance training specifically is real but thinner than for aerobic exercise. Score reflects that asymmetry honestly; the article says so plainly.
• Sleep 2. Modest, consistent across the literature, especially in older adults. Not the dominant effect; not zero.
• Beauty (cumulative) 4 vs 5. Stayed at 4. The aging-trajectory case is strong but not transformative in the cosmetic-procedure sense the level-5 anchor implies.
• Controversy 1. Field debates on optimal volume and frequency (Schoenfeld vs. some practitioner camps) are real but minor-at-the-margins, not foundational. No legitimate camp argues lifting is net-bad or net-neutral.

Contraindications. The closed-vocabulary list includes uncontrolled-hypertension and cardiac-condition. The article's warning callout covers additional pre-clearance cases (recent eye surgery / active retinopathy, hernia, aortic aneurysm) that aren't in the closed vocabulary but warrant clinician sign-off; these surface in the warning callout, not the meta list.

Excluded as their own subjects.

• Specific exercise selection / form tutorials — different surface, would balloon the article.
• Powerlifting / bodybuilding / sport-specific programming — adjacent to the catalogue's reader (a general adult), would crowd the protocol section.
• Pre-/postnatal lifting protocols — needs its own entry; pregnancy is its own contraindication vocabulary token even though continuing established training is generally safe.
• Menopause and HRT context for women — flagged as separate-entry candidate.
• Blood-flow restriction training — promising for older / injured trainees but its own evidence base; separate entry.

Future-link candidates (entries to wire in when they exist): creatine (already exists per the spec example), protein-intake, sleep, cardiovascular-exercise / vo2max-training, balance-and-falls-prevention, menopause-hrt, bone-density-screening (DEXA).

Separate-entry candidates surfaced during writing: the menopausal / postmenopausal lifting case is large enough on its own evidence (LIFTMOR cohort, hormonal context) to warrant a dedicated entry once the women's-health section grows; blood-flow restriction training likewise.

Hard decision: dosing the protocol section's specificity. The literature supports a range of dose recommendations. Chose the conservative-but-effective synthesis (10 hard sets/muscle/week, 5–15 reps, RIR 1–3, 2–3 sessions, compound-led) rather than dwell on the volume-optimisation debate. The dossier carries the broader picture for any reviewer who wants it; the article's reader doesn't.